Related Experiment Video
Updated: Sep 26, 2025

Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b
Published on: November 11, 2016
Suppressing leukocyte Kv1.3-channels by commonly used drugs: A novel therapeutic target for schizophrenia?
Yasuhiro Sato1, Ryo Kuwana1, Itsuro Kazama1
1Miyagi University, School of Nursing, Taiwa-cho, Miyagi, Japan.
Abstract:
Recent studies revealed the involvement of "chronic inflammation" in the pathogenesis of schizophrenia. In schizophrenia and some neurodegenerative disorders that are caused by inflammation, T-lymphocytes and macrophages were hyperactivated or proliferated in the central nervous system, being accompanied by the overexpression of delayed rectifier K+-channels (Kv1.3) within the cells. In our previous basic studies, in addition to nonsteroidal anti-inflammatory drugs (NSAIDs) and statins, antibiotics (clarithromycin, chloroquine), anti-hypertensive drugs (nifedipine, benidipine, diltiazem, verapamil) and anti-allergic drugs (cetirizine, fexofenadine, azelastine, terfenadine) strongly suppressed the Kv1.3-channel activity and pro-inflammatory cytokine production from lymphocytes. Given such pharmacological properties of these commonly used drugs, they may be useful in the treatment of schizophrenia, in which the enhanced cellular immunity and the subsequent release of excessive cytokines are responsible for the pathogenesis.
More Related Videos
Related Concept Videos
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...

